8-K - MIRA - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date<br> of Report (Date of earliest event reported): August 7, 2024
MIRA PHARMACEUTICALS, INC.
(Exact<br> Name of Registrant as Specified in its Charter)

Florida	001-41765	85-3354547
(State<br> or Other Jurisdiction<br><br> of Incorporation)	(Commission<br><br> File Number)	(IRS<br> Employer<br><br> Identification No.)

1200Brickell Avenue, Suite 1950 #1183

Miami,Florida

33131

(Address of Principal Executive Offices)

(737)289-0835

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title<br> of each class	Trading<br> Symbol	Name<br> of each exchange on which registered
Common<br> Stock, $0.0001 par value per share	MIRA	The<br> Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item8.01 Other Events

On August 7, 2024, MIRA Pharmaceuticals, Inc. (the “Company”) received notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price requirement. The Company has resolved all issues cited by Nasdaq and is now in good standing with all applicable requirements for continued listing on the Nasdaq.

The Company is pleased to have regained compliance and will continue to adhere to Nasdaq’s listing standards.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MIRA PHARMACEUTICALS, INC.
Date:<br> August 8, 2024	By:	/s/ Erez Aminov
	Erez<br> Aminov
	Chief<br> Executive Officer